Anticoagulants Market Size 2020 | Increasing Number of Company Mergers Will Provide Impetus to Growth, Says Fortune Business Insights™ | Medgadget

Anticoagulants Market Size 2020 | Increasing Number of Company Mergers Will Provide Impetus to Growth, Says Fortune Business Insights™ | Medgadget

Anticoagulants Market Size 2020 | Increasing Number of Company Mergers Will Provide Impetus to Growth, Says Fortune Business Insights™ February 4th, 2020 Fortune Business Insights Releases The global anticoagulants market size is projected to reach 45.50 billion by the end of 2026. According to a report published by Fortune Business Insights, titled “Anticoagulants Market Size, Share & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026,” the market was worth USD 21.45 billion in 2018 and will exhibit a CAGR of 9.9% during the forecast period,2019-2026. The report includes thorough compilation of the quantitative analysis of the industry for the period of 12 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period. This study includes a widespread analysis of the key segments of the industry. This analysis sheds light in the current trends and opportunities in the Anticoagulants Market. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/anticoagulants-market-101807 Key Points of the Anticoagulants Market Report: The report provides a basic overview of the industry including its definition, applications, and manufacturing technology. The report also explores the major international players in detail. In this part, the report presents the company profile, product specifications, capacity, and production value along with the market shares for each company. Through the statistical analysis, the study depicts the global market including capacity, production, production value, cost/profit, and supply/demand from an international perspective. Considering segmentation, the market is divided in terms of product, end-use, company, region, and other important aspects. Each of these categories forms an important base point for the competitive landscape analysis. The report then estimates the market development and trends of the Anticoagulants Market. Increasing Number of Company Mergers Will Aid Market Growth Several growth stimulating factors have been analyzed and discussed in detail. Among all factors, the increasing number of company mergers have had the highest impact on the market. In February 2019, Novartis AG and Blackstone’s LifeSciences announced the launch of Anthos Therapeutics. The company is aiming for the research and development of drugs that include anticoagulants as a prime pipeline candidate. Increasing number of drug approvals is another factor that has constituted an increase in the global anticoagulants market size in recent years. Janssen Pharmaceuticals’ Rivaroxaban is an example of a recent drug approval that has had a direct impact on the market. Top manufactures of Anticoagulants Market are: Bristol-Myers Squibb Company



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More